对JTE-151的发现和SAR:用于临床开发的新型RORγ抑制剂
Takaki Maeba1,2, Kazuyuki Hirata1, Masayuki Kotoku3
1Central Pharmaceutical Research Institute, Takatsuki Research Center, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.
Journal of medicinal chemistry
|January 3, 2024
概括
开发可口服的RORγ抑制剂如JTE-151至关重要. 这项研究侧重于类似药物的特性,导致选择性RORγ抑制剂,在临床试验中显示出良好的安全性和药理动力学.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 与视网类药物相关的孤儿受体玛 (RORγ) 抑制剂已经被研究了十多年.
- 尽管临床试验取得了进展,但没有RORγ抑制剂进入市场,这表明有发展挑战.
- 主要障碍包括核受体连接体的选择性不足和不良的物理化学特性.
研究的目的:
- 为了解决RORγ抑制剂的发展障碍.
- 进行结构-活性关系 (SAR) 调查,优先考虑类似药物的特性.
- 开发一种具有选择性和口服可用的RORγ抑制剂,具有改进的类似药物的特性.
主要方法:
- 集中SAR探索的重点是增强"药物相似性"指数.
- 在抑制剂设计过程中优先考虑物理化学性质和选择性.
- 一种化合物JTE-151进入人类临床试验的进展.
主要成果:
- 鉴定和产生一种口服可用的RORγ抑制剂,JTE-151.
- JTE-151展示了高度选择性的配置文件.
- 该化合物在临床试验中表现出良好的代谢稳定性,有利的药理动力学 (PK) 和没有严重不良事件 (SAE).
结论:
- SAR调查成功地产生了一种口服可用的RORγ抑制剂,JTE-151.
- JTE-151的良好的选择性,代谢稳定性和临床安全性概况表明它是一个可行的治疗候选者.
- 这种优先考虑药物相似性的方法可以减轻RORγ抑制剂开发中的常见风险.
相关概念视频
Structure-Activity Relationships and Drug Design
726
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
726
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Receptor Tyrosine Kinases
13.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
982
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
982
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
567
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
567


